Zydus Lifesciences scored a major landmark earlier this year when it scooped the first US Food and Drug Administration approval for a generic version of AstraZeneca’s Farxiga (dapagliflozin), “the fastest growing SGLT2 inhibitor globally.”
Zydus Walks Away From US Dapagliflozin Appeal, ANDA Discontinued
ANDA Sponsor And AstraZeneca Disagreed On Chances Of Settlement
In a blow to potential US generic competition, Zydus Cadila has withdrawn its appeal to an unfavorable federal ruling involving a US Farxiga (dapagliflozin) patent.
More from Generics
More from Products
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
The US FDA has deemed certain CRO Raptim Research’s in vitro bioequivalence studies as “not acceptable” and raised concerns over its in vivo study methods. Will other agencies follow suit?
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.